Eisai Drops Perampanel In Parkinson’s, Plans First Neuropathy Submission For 2010
This article was originally published in PharmAsia News
Executive Summary
Eisai announced April 11 it has abandoned development of its novel AMPA receptor antagonist perampanel in Parkinson's disease after a second Phase III trial failed, but the Tokyo firm is forging ahead with the compound in other neurological indications